Clinical characteristics of non-infectious uveitis treated with and without systemic immunomodulatory therapy
- PMID: 37972648
- DOI: 10.1016/j.jcjo.2023.10.002
Clinical characteristics of non-infectious uveitis treated with and without systemic immunomodulatory therapy
Abstract
Objective: To compare the patient characteristics and long-term outcomes for those treated with and without systemic immunomodulatory therapy (IMT) for non-infectious uveitis (NIU).
Design: Retrospective cohort study.
Participants: All consecutive adults with NIU receiving care at 5 uveitis subspecialty tertiary care clinics between 2010 and 2021.
Methods: Clinical outcomes were evaluated on initial presentation and at the last available follow-up. The main outcome measures were baseline characteristics and final visual acuity.
Results: A total of 914 NIU patients (418 IMT, 496 non-IMT) with a median age of 51.0 years and 57.4% female were identified. Over half the patients had bilateral disease, with a significantly higher proportion of bilateral cases in the IMT group compared with the non-IMT group (p < 0.001). The IMT group was more likely to have chronic uveitis (p < 0.001), with a higher proportion of patients experiencing cataracts and cystoid macular edema (p < 0.001 for both). A significantly higher proportion of non-IMT patients had anterior uveitis and an idiopathic etiology (p < 0.001). Overall, visual acuity improved significantly from baseline to last follow-up in the entire cohort (p < 0.001), with a slightly better improvement in the IMT group. Multivariable linear regression analysis suggested that baseline visual acuity and panuveitis were significant predictors of final visual acuity (p < 0.001 for both).
Conclusions: NIU patients on IMT are often younger, suffer from bilateral and chronic uveitis, and are more likely to have ocular complications. Those in the non-IMT group are more likely to have anterior idiopathic NIU. Baseline visual acuity and panuveitis are the main predictors of final vision outcomes among patients with NIU.
Copyright © 2023. Published by Elsevier Inc.
Similar articles
-
Long-term outcomes of noninfectious uveitis treated with systemic immunomodulatory therapy: a retrospective case series.Can J Ophthalmol. 2025 Feb;60(1):e133-e143. doi: 10.1016/j.jcjo.2024.05.005. Epub 2024 Jun 15. Can J Ophthalmol. 2025. PMID: 38889882
-
Characteristics of ocular hypertension and uveitic glaucoma among patients with noninfectious uveitis.Can J Ophthalmol. 2024 Dec;59(6):430-438. doi: 10.1016/j.jcjo.2024.02.003. Epub 2024 Feb 29. Can J Ophthalmol. 2024. PMID: 38431271
-
Malignancy Risk Associated With the Use of Systemic Immunomodulatory Therapy in the Management of Noninfectious Uveitis.Am J Ophthalmol. 2024 Sep;265:241-247. doi: 10.1016/j.ajo.2024.04.015. Epub 2024 Apr 26. Am J Ophthalmol. 2024. PMID: 38679356
-
Adult patients with uveitis associated with juvenile idiopathic arthritis: a retrospective review.Can J Ophthalmol. 2017 Oct;52(5):458-462. doi: 10.1016/j.jcjo.2017.01.011. Epub 2017 Mar 18. Can J Ophthalmol. 2017. PMID: 28985804 Review.
-
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative.Ophthalmology. 2018 May;125(5):757-773. doi: 10.1016/j.ophtha.2017.11.017. Epub 2018 Jan 6. Ophthalmology. 2018. PMID: 29310963
MeSH terms
Substances
LinkOut - more resources
Full Text Sources